Binding of Clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system

Immunogenic and Protective Potentials of Recombinant Receptor Binding Domain and a C-Terminal Fragment of Clostridium botulinum Neurotoxin Type E

Clostridium Botulinum Type E neurotoxin heavy chain consists of two domains: the translocation domain asthe N-terminal half and the binding domain as the Cterminal half (Hc). One effective way to neutralize botulinum neurotoxin is to inhibit binding of this toxin to neuromuscular synapses with antibodies against binding domain. Two synthetic genes, coding for Hc (the full length binding d...

Cloning, Expression and Purification of Clostridium botulinum Neurotoxin Type E Binding Domain

Expression and Purification of Neurotoxin-Associated Protein HA-33/A from Clostridium botulinum and Evaluation of Its Antigenicity

Background: Botulinum neurotoxin (BoNT) complexes consist of neurotoxin and neurotoxin-associated proteins. Hemagglutinin-33 (HA-33) is a member of BoNT type A (BoNT/A) complex. Considering the protective role of HA-33 in preservation of BoNT/A in gastrointestinal harsh conditions and also its adjuvant role, recombinant production of this protein is favorable. Thus in this study, HA-33 was expr...

Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes.

After treatment of Clostridium botulinum type A neurotoxin with papain, three fragments (Mrs, 101,000, 45,000, and 43,000) were purified by hydrophobic and ion-exchange chromatography with a high-performance liquid chromatographic system. Immunoblotting analyses with monoclonal antibodies showed that the 101,000-dalton fragment consisted of the light chain and a part of the heavy chain (H-1 fra...

بررسی ایمنی‌زایی نانوذرات کیتوسان حاوی پروتئین نوترکیب ناحیه اتصال‌دهنده نوروتوکسین بوتولینوم تیپ E در موش

Abstract Background and purpose: Clostridium botulinum neurotoxins are the most potent toxins that cause the life-threatening botulism syndrome in humans and animals. Researches have shown that the binding domain of the botulinum neurotoxin type E has a high immunogenicity effect that could be used as an efficient recombinant vaccine. The recombinant vaccines are not potent enough to stimulate...